Incyclix Bio
Durham
About Incyclix Bio
Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers. Founded by Patrick Roberts, Jay Strum, John Bisi, and Fred Eshelman in 2020 and is headquartered in Durham, North Carolina.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $47.2M
- Funding stage: Early Stage Venture
- Last round: Series B (Aug 2025)
- Website: incyclixbio.com
- Phone: (919) 328-0003
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/incyclix-bio-97159 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.